Depo-Provera Lawsuit 2026: MDL, Claims & Settlements

Quick Answer
– The Depo-Provera lawsuit alleges that Pfizer failed to adequately warn users that prolonged use of the injectable contraceptive significantly increases the risk of developing intracranial meningiomas.
– Women who used Depo-Provera for 12 months or longer and received a meningioma diagnosis are the primary qualifying claimants in this litigation.
– Settlement amounts have not been formally established, but plaintiffs' attorneys are projecting individual payouts ranging from $100,000 to over $1,000,000 depending on injury severity, surgical intervention, and duration of use.

Case Snapshot

Federal litigation over Depo-Provera is moving at pace. The depo-provera lawsuit now sits in a centralized federal MDL in Chicago, with Pfizer facing thousands of individual personal injury claims from women who developed intracranial brain tumors after extended use of the injectable contraceptive.

The core allegation is not that the drug caused tumors in every user. The claim is specific: Pfizer knew, or should have known, that medroxyprogesterone acetate carries a statistically elevated meningioma risk with prolonged use, and the company failed to update its warning label accordingly.

This may also interest you: Amazon Prime Lawsuit 2026: Claims, Settlement & Who Qualifies

Scientific support for that allegation is substantial. A major French pharmacovigilance study published in the British Medical Journal in 2024 reported a roughly fivefold increased risk of intracranial meningioma in long-term Depo-Provera users. That research is now central to plaintiffs' general causation arguments in MDL 3140.

This article covers the current litigation structure, who qualifies, what compensation may look like, and where the case stands heading into mid-2026.

What Is the Depo-Provera Lawsuit in 2026?

The Depo-Provera lawsuit is a mass tort litigation targeting Pfizer Inc. and its subsidiary Pharmacia LLC over alleged failure-to-warn defects in the marketing and labeling of Depo-Provera, a widely used injectable hormonal contraceptive.

Plaintiffs allege that extended use of medroxyprogesterone acetate, the active ingredient in Depo-Provera, causes the growth of intracranial meningiomas. These are tumors arising from the meninges, the protective membrane layers surrounding the brain and spinal cord.

The lawsuit does not challenge the drug's effectiveness as a contraceptive. The legal theory centers on what Pfizer knew about meningioma risk, when it knew it, and why that risk was never adequately disclosed to prescribing physicians or patients.

Key allegations include:

• Failure to warn consumers and physicians of a known meningioma risk
• Defective labeling under FDA product liability standards
• Negligence in post-market surveillance of adverse event reports
• Fraudulent concealment of known risk data in some individual complaints

*Attorney Insight: Attorneys handling these claims note that the failure-to-warn theory is particularly strong where a client can show a prescribing physician testified they would have discussed the meningioma risk had it appeared in the label, giving rise to a learned intermediary causation chain.*

Understanding Depo-Provera MDL 3140 in Federal Court

MDL 3140 is the formal federal multidistrict litigation docket consolidating Depo-Provera personal injury claims from across the country into a single federal court.

The Judicial Panel on Multidistrict Litigation transferred the cases to the Northern District of Illinois in December 2024. Judge Matthew F. Kennelly was assigned to preside. The Northern District of Illinois, sitting in Chicago, handles some of the largest pharmaceutical MDLs in the country, and this consolidation follows established protocol for managing complex mass tort discovery.

MDL consolidation does not merge individual lawsuits into one. Each plaintiff retains their individual case. The MDL process centralizes pretrial proceedings: depositions of corporate executives, expert witness challenges, document production from Pfizer, and case management scheduling.

What MDL 3140 includes:

• A master long-form complaint setting out all shared allegations
• Case Management Orders governing discovery timelines
• A Plaintiffs' Steering Committee coordinating litigation strategy
• Bellwether trial selection process, expected to begin shaping in 2026
• Daubert motions challenging or defending general causation experts

*Attorney Insight: Attorneys handling these claims point to the bellwether trial schedule as the most consequential near-term milestone, since bellwether verdicts in pharmaceutical MDLs typically drive global settlement negotiations more directly than any other single event.*

Pfizer's Role and Legal Exposure in This Litigation

Pfizer Inc. is the primary defendant in the Depo-Provera lawsuit because it acquired Pharmacia Corporation in 2003, along with the full Depo-Provera product line and all associated liabilities.

Pharmacia first brought Depo-Provera to the U.S. market as a contraceptive in 1992. The FDA approved it as a hormonal birth control injection administered every three months. Pfizer has marketed, distributed, and profited from the product since the 2003 acquisition.

The legal significance of that acquisition is not trivial. Pfizer inherited not only the brand but also Pharmacia's internal research files, adverse event reports, and any prior communications with the FDA regarding meningioma risk signals. Plaintiffs' discovery requests in MDL 3140 are focused heavily on those pre-acquisition and post-acquisition internal records.

Pfizer's stated legal posture includes:

• Denial that Depo-Provera causes meningiomas at a clinical level requiring label changes
• Arguments that the drug's label has always complied with FDA requirements
• Challenges to the French BMJ study's applicability to U.S. patient populations
• General causation Daubert challenges against plaintiffs' neurosurgical and epidemiological experts

*Attorney Insight: Attorneys handling these claims note that Pfizer's litigation strategy in pharmaceutical MDLs typically involves aggressive early Daubert motions, making the court's ruling on general causation experts the single most important near-term legal event for every claimant in the MDL.*

Pfizer's Depo-Provera Revenue Context:

Depo-Provera has been one of the most widely administered injectable contraceptives globally for three decades. Tens of millions of doses have been dispensed in the United States alone. That scale of use means the potential claimant pool is large, and Pfizer's legal exposure in a fully litigated MDL could reach figures comparable to other major pharmaceutical mass torts.

Litigation Watch: MDL 3140 is consolidating individual claims in the Northern District of Illinois under Judge Kennelly, Pfizer is contesting general causation, and bellwether trial scheduling in 2026 will define the financial shape of any global resolution.

The Depo-Provera Meningioma Lawsuit: The Core Medical Claim

The depo-provera meningioma lawsuit rests on a specific biological mechanism: prolonged exposure to synthetic progestogens, particularly medroxyprogesterone acetate, stimulates progesterone receptors found on meningeal cells, promoting abnormal cell proliferation.

Meningiomas are the most common primary intracranial tumors in adults. Most are benign in the traditional oncological sense, meaning they do not metastasize. But benign does not mean harmless. A meningioma pressing against the brain can cause seizures, vision loss, cognitive decline, personality changes, and debilitating headaches. Surgical resection carries real risk of permanent neurological deficits.

The 2024 BMJ study from French researchers at the Agence Nationale de Sécurité du Médicament et des Produits de Santé (ANSM) provided the most significant epidemiological evidence yet. It reported that women using high-dose progestogen contraceptives, including medroxyprogesterone acetate, faced approximately a 5.6-fold increased risk of intracranial meningioma requiring surgery.

The scientific evidence plaintiffs are relying on:

• The 2024 BMJ / ANSM pharmacovigilance study (cohort of over one million French women)
• Prior European regulatory actions restricting progestogen use in meningioma patients
• Internal Pfizer adverse event reports obtained through MDL discovery
• Neurosurgical expert testimony on progesterone receptor expression in meningioma tissue

*Attorney Insight: Attorneys handling these claims note that the presence of progesterone receptor-positive meningioma tissue in a surgical pathology report significantly strengthens individual specific causation arguments, particularly in jurisdictions using the substantial factor causation standard.*

Brain Tumor Injuries at the Center of Depo-Provera Claims

Brain tumor injuries in the Depo-Provera context refer specifically to intracranial meningiomas, not all brain cancers. That distinction matters for both medical and legal purposes.

Plaintiffs are not alleging that Depo-Provera causes glioblastoma, astrocytoma, or other aggressive brain malignancies. The claim is narrowly focused on meningiomas, which are typically slow-growing tumors arising from the meningeal tissue. Their connection to hormonal stimulation, particularly progestogen exposure, has been documented in peer-reviewed neurosurgery literature for over two decades.

The practical consequences of meningiomas can be severe even when the tumor is classified as grade I or benign. Surgical removal may require craniotomy, a procedure with meaningful risks of stroke, infection, and functional neurological injury depending on tumor location. Tumors near the cavernous sinus, optic nerve sheath, or sphenoid wing are particularly difficult to fully resect.

Meningioma injury categories relevant to litigation:

*Attorney Insight: Attorneys handling these claims consistently flag that tumor location in surgical records is as important as grade, since tumors requiring complex skull base surgery generate far higher documented damages than tumors resected through straightforward procedures.*

Symptoms and Injuries That Support a Depo-Provera Claim

Qualifying symptoms in the Depo-Provera lawsuit are those clinically associated with intracranial meningioma development. Not all Depo-Provera users who experienced side effects have viable claims.

A viable claim requires a diagnosed meningioma confirmed by MRI, CT imaging, or surgical pathology. Symptoms alone are insufficient. Those symptoms, however, typically drove the diagnostic workup that led to the meningioma discovery.

Documented symptoms frequently preceding a meningioma diagnosis in plaintiffs' records:

• Persistent or worsening headaches not explained by other diagnoses
• Seizures or new-onset epilepsy in an adult with no prior history
• Progressive vision changes, including blurring, double vision, or field defects
• Tinnitus (ringing in the ears) or sudden hearing loss
• Facial numbness or weakness
• Cognitive changes including memory impairment and confusion
• Loss of smell (anosmia) when a frontal or olfactory groove tumor is involved
• Limb weakness or coordination problems

Documented injuries in filed claims:

• Craniotomy or craniectomy for tumor removal
• Stereotactic radiosurgery (Gamma Knife, CyberKnife)
• Post-surgical neurological deficits (vision loss, motor impairment, speech difficulty)
• Seizure disorder requiring ongoing anticonvulsant medication
• Tumor recurrence requiring second surgical intervention
• Permanent disability affecting work capacity

*Attorney Insight: Attorneys handling these claims consistently note that a well-documented medical record showing the timeline from symptom onset through meningioma diagnosis, including all imaging studies, is the single most important piece of evidence in establishing both causation and damages.*

Litigation Watch: The medical foundation of the Depo-Provera lawsuit is the meningioma-progestogen link established in European pharmacovigilance data, and individual claim strength turns on surgical pathology reports, imaging timelines, and documented functional impairment.

Who Qualifies for the Depo-Provera Lawsuit?

Qualifying for the Depo-Provera lawsuit requires meeting a defined combination of use history and injury criteria. Meeting some criteria but not all significantly weakens or eliminates a claim.

The threshold most plaintiffs' firms are applying requires a minimum of 12 months of Depo-Provera use and a confirmed meningioma diagnosis. Some firms apply a stricter threshold of 24 months of continuous or cumulative use based on the dosage-response data in the 2024 BMJ study.

Core eligibility criteria:

Who likely does not qualify:

• Women who used Depo-Provera for fewer than 12 months total
• Women with a prior meningioma diagnosis predating Depo-Provera use
• Women whose brain tumor is not classified as meningioma (other histological types are not currently covered in MDL 3140 claims)
• Individuals whose claims are time-barred under applicable state law

*Attorney Insight: Attorneys handling these claims note that pharmacy benefit records, Medicaid or insurance billing histories, and clinic injection records can often substitute for a missing prescription in establishing qualifying use duration, making it worth retaining an attorney even when personal records are incomplete.*

Is the Depo-Provera Lawsuit a Class Action?

The Depo-Provera lawsuit is not a certified class action. This is one of the most frequently misunderstood aspects of this litigation.

MDL 3140 is a mass tort consolidation, not a class action. Each plaintiff files an individual personal injury claim. No class has been certified, and based on the individual nature of the medical injuries alleged, class certification is unlikely to be pursued or granted.

The practical difference is significant. In a class action, a single judgment or settlement is divided among all class members, often resulting in small per-person recoveries. In this mass tort structure, each claimant's case is evaluated individually. Compensation is based on that person's specific diagnosis, severity of injury, duration of drug use, and documented economic losses.

On a related note, check out Schedule 1 Lawsuit: What Plaintiffs Need to Know 2026

Mass Tort vs. Class Action: Key Differences

*Attorney Insight: Attorneys handling these claims consistently explain to clients that the mass tort structure is more favorable for serious injury claimants than a class action would be, since a meningioma patient who required surgery recovers far more in an individual settlement than they would in a per-capita class distribution.*

Depo-Provera Lawsuit Settlement Amount: What the Numbers Show

No global settlement has been reached in the Depo-Provera lawsuit as of early 2026. The litigation is still in the discovery and case management phase.

That said, plaintiffs' attorneys and legal analysts tracking MDL 3140 are modeling potential settlement values based on comparable pharmaceutical mass tort precedents. The closest analogues are the transvaginal mesh MDLs, the Risperdal gynecomastia settlement, and the NuvaRing litigation, each of which produced individual recoveries scaled to injury severity.

What drives settlement value in this litigation:

• Duration of Depo-Provera use (more injections, stronger causation argument)
• Grade and size of meningioma at diagnosis
• Whether surgery was required and its complexity
• Documented neurological deficits post-treatment
• Lost income and lost earning capacity
• Age at diagnosis and projected future medical costs
• Strength of causation chain from prescribing records

Comparable pharmaceutical mass tort settlement ranges (for context):

*Attorney Insight: Attorneys handling these claims note that brain surgery cases carry inherently higher damages potential than soft-tissue pharmaceutical injury cases because the surgical risk, potential neurological permanence, and documented impact on daily functioning are easier to quantify and present to a jury.*

Litigation Watch: No global Depo-Provera settlement exists yet, but bellwether verdicts expected in 2026 and 2027 will anchor the value range Pfizer uses in negotiations, making it premature but not premature to retain counsel.

Depo-Provera Lawsuit Payout Per Person: Tier Projections

Individual payout projections in the Depo-Provera lawsuit depend on which injury tier a claimant falls into. Plaintiffs' attorneys are informally using tiered frameworks to manage client expectations and case valuation.

No settlement matrix has been formally adopted by MDL 3140 as of early 2026. What exists are internal valuation models used by leading plaintiffs' firms, calibrated against the general causation science and comparable mass tort outcomes.

Projected individual payout tiers (based on attorney projections, not confirmed settlement amounts):

These ranges are informed projections, not guaranteed outcomes. Actual settlements depend on Pfizer's global resolution posture, bellwether trial results, and individual case facts.

*Attorney Insight: Attorneys handling these claims point to the importance of preserving all post-diagnosis medical records, including neuropsychological testing, physical therapy records, and employment records reflecting time lost, since these documents collectively build the damages case that drives tier placement.*

Depo-Provera Lawsuit Filing Deadline: When You Must Act

There is no single universal filing deadline for the Depo-Provera lawsuit. Filing deadlines are governed by each state's statute of limitations for personal injury product liability claims.

Federal MDL consolidation does not create a new, unified statute of limitations. Each claimant's deadline is set by the law of the state where they were injured (or, in some cases, where the product was purchased or prescribed). Those deadlines vary significantly.

General rule for most states: The statute of limitations for product liability personal injury claims runs two to three years from the date a plaintiff knew or reasonably should have known that their injury was connected to Depo-Provera use.

The discovery rule is critical. In most jurisdictions, the clock does not start the moment a meningioma is diagnosed. It starts when a claimant knew or had reason to know that Depo-Provera may have caused the tumor. This distinction has saved many time-barred cases when properly argued.

*Attorney Insight: Attorneys handling these claims note that the discovery rule argument is strongest when a claimant can show they had no awareness of the meningioma-Depo-Provera link until the 2024 BMJ study received widespread media coverage, which resets the limitations clock in many states.*

Why acting in 2026 matters:

Women diagnosed with meningiomas in 2022 or 2023 who live in states with strict two-year statutes may already be approaching or past their filing window unless the discovery rule applies. Waiting further narrows options significantly.

Depo-Provera Lawsuit Statute of Limitations by State

The statute of limitations for the Depo-Provera lawsuit varies by state and by the specific facts of each claimant's case. The table below reflects general product liability personal injury statutes.

State-by-state limitations overview (selected states with high claim volume):

This table reflects general statutory periods. Individual circumstances may alter the applicable deadline. A pharmaceutical product liability attorney must be consulted for a case-specific assessment.

*Attorney Insight: Attorneys handling these claims note that Florida's 2023 reform reducing the limitations period from four years to two years has created particular urgency for Florida-based claimants diagnosed in 2021 or 2022, who may have assumed they had more time.*

Litigation Watch: Statute of limitations deadlines are state-specific and running now, the discovery rule is the primary protection for late-diagnosing claimants, and Florida's 2023 tort reform makes that state's claimants the most time-sensitive group in MDL 3140.

Which States Have the Most Depo-Provera Lawsuit Activity?

Depo-Provera lawsuit activity is concentrated in states with large populations, active plaintiffs' bars, and high historical rates of Depo-Provera prescribing.

California, Texas, Florida, New York, Illinois, Pennsylvania, and Ohio account for the largest share of individual cases now consolidated in MDL 3140. These states reflect both population density and the geographic reach of hospital systems that historically administered Depo-Provera as a primary contraceptive in community health and reproductive health clinic settings.

States with significant claim volume in MDL 3140:

Depo-Provera was heavily administered in federally qualified health centers, Planned Parenthood affiliates, military health facilities, and public health clinics. Women who received the drug through these systems may face more difficulty locating records, but records can often be retrieved through provider requests or state Medicaid databases.

*Attorney Insight: Attorneys handling these claims note that military and VA health system records are retrievable through federal records requests, and women who received Depo-Provera through TRICARE or military clinics should not assume their records are inaccessible.*

How to Join the Depo-Provera Lawsuit

Joining the Depo-Provera lawsuit means retaining a qualified plaintiffs' attorney, not filing directly with a court or signing up on a website.

There is no public registration portal for MDL 3140. Claimants enter the litigation by retaining an individual attorney who then files a short-form complaint that is transferred into the MDL. The process is handled entirely by counsel.

The practical steps to pursue a Depo-Provera claim:

1. Gather your medical records. Obtain all MRI, CT, and surgical pathology reports confirming meningioma diagnosis.
2. Document your Depo-Provera use. Request injection records from your OB-GYN, family physician, or clinic. Request pharmacy records or insurance billing records showing injection dates.
3. Consult a pharmaceutical product liability attorney. Most handle these cases on a contingency fee basis, meaning no upfront cost to you.
4. Sign a retainer agreement. Your attorney files your individual short-form complaint into MDL 3140.
5. Participate in plaintiff fact sheet completion. The MDL court requires each plaintiff to submit a detailed plaintiff fact sheet covering medical history, drug use timeline, and injury documentation.
6. Await case management progress. Your case moves with the MDL through discovery, bellwether selection, and eventually settlement negotiations or individual trial.

*Attorney Insight: Attorneys handling these claims note that the plaintiff fact sheet in MDL 3140 is a formal court-required document, not just an intake form, and errors or omissions in that document can meaningfully affect case value during settlement evaluation.*

Depo-Provera Lawsuit Update 2026: Where the Case Stands Now

The Depo-Provera lawsuit in 2026 is in the active pretrial phase. The MDL has moved through its initial organizational structure and is now in a period of intensive document discovery and expert witness development.

Pfizer is engaged in the production of internal documents responsive to plaintiffs' discovery requests. These include internal safety committee minutes, adverse event reporting files, communications with the FDA regarding label revisions, and marketing documents related to Depo-Provera's promotion to community health providers.

On the plaintiffs' side, the Plaintiffs' Steering Committee has retained general causation experts in neuro-oncology, epidemiology, and pharmacology. Those experts are preparing reports supporting the biological plausibility and epidemiological evidence linking medroxyprogesterone acetate to meningioma development.

Explore this too: Taxotere Lawsuit Law Firm: Your Full 2026 Case Guide

Key 2026 litigation milestones to watch:

The claim volume in MDL 3140 is growing. Each month that passes without a global settlement means more cases are added to the docket, which increases Pfizer's aggregate exposure but also lengthens the timeline to resolution.

*Attorney Insight: Attorneys handling these claims note that in pharmaceutical MDLs of this scale, global settlement discussions typically do not begin in earnest until at least one or two bellwether trials have produced verdicts that anchor both sides' valuation models.*

Litigation Watch: MDL 3140 is in active discovery and expert preparation in 2026, bellwether selection is the next major milestone, and Pfizer's document production may produce internal communications that materially strengthen the failure-to-warn claim before any trial occurs.

Current Status of the Depo-Provera Litigation

The current status of the Depo-Provera litigation is active and accelerating. Case volume in MDL 3140 has grown significantly since the MDL transfer was completed in late 2024.

Judge Matthew F. Kennelly has issued a series of Case Management Orders establishing the procedural framework for pretrial proceedings. The orders govern the timeline for fact discovery, the schedule for expert disclosures, and the process for selecting bellwether cases from the larger MDL pool.

Pfizer has not indicated any willingness to pursue early settlement. The company's litigation posture in pharmaceutical MDLs has historically been to contest general causation aggressively through Daubert proceedings before any settlement discussions begin. That pattern is consistent with what MDL observers are seeing in MDL 3140.

What the current status means for claimants:

• Cases filed now are being assigned short-form complaint numbers and integrated into the MDL
• Plaintiff fact sheets are being processed
• Individual cases will not go to trial before bellwether trials establish a value framework
• Most claimants should expect a resolution timeline of two to four years from the time they file

*Attorney Insight: Attorneys handling these claims consistently advise clients that patience is required in large pharmaceutical MDLs, but that filing as early as possible ensures the client's case is in the MDL when bellwether verdicts drive settlement pressure, rather than being a latecomer claim that may receive less favorable treatment in a global resolution.*

What Kind of Attorney Handles the Depo-Provera Lawsuit?

The Depo-Provera lawsuit is handled by pharmaceutical product liability attorneys who specialize in mass tort litigation. This is a distinct legal specialty.

Not every personal injury attorney has the infrastructure to handle a pharmaceutical MDL case competently. Cases in MDL 3140 require an attorney who understands complex medical causation, who can work within the MDL's case management structure, and who has experience managing plaintiff fact sheets, deposition coordination, and settlement matrix negotiations specific to mass torts.

What to look for in a Depo-Provera attorney:

• Demonstrated history handling pharmaceutical mass tort or MDL cases
• Contingency fee arrangement (you pay nothing unless they recover compensation)
• Familiarity with MDL 3140 specifically, including its current case management orders
• Capacity to obtain and review your medical records independently
• Clear communication about the litigation timeline and what to expect at each stage

What these attorneys are not:

• General practice attorneys handling car accidents or slip-and-fall claims
• Attorneys who simply refer your case to another firm without disclosing that arrangement
• Online claim registration services that are not law firms

*Attorney Insight: Attorneys handling these claims note that some lead generation companies are marketing themselves as lawsuit participation portals when they are actually referral services without litigation capability, and that claimants should confirm they are speaking directly with a licensed attorney at the firm that will actually represent them.*

Typical fee structure:

Frequently Asked Questions

What is the Depo-Provera lawsuit about?

The Depo-Provera lawsuit claims that Pfizer failed to adequately warn users that long-term use of the injectable contraceptive significantly increases the risk of developing intracranial meningiomas, a type of brain tumor.

The litigation is consolidated in MDL 3140 in the Northern District of Illinois, with thousands of individual personal injury claims from women who developed meningiomas after extended Depo-Provera use.

The core legal theory is failure to warn, supported by a major 2024 BMJ epidemiological study showing roughly a fivefold increased meningioma risk in long-term users.

How much is the Depo-Provera lawsuit settlement per person?

No global settlement has been reached as of early 2026, so there is no confirmed per-person figure.

Attorneys are projecting individual payouts ranging from $50,000 to over $2,000,000, depending on injury severity, whether surgery was required, and the extent of permanent neurological impairment.

Bellwether trial verdicts in 2026 and 2027 will anchor the value range used in eventual global settlement negotiations.

Who qualifies for the Depo-Provera lawsuit in 2026?

Women who used Depo-Provera for at least 12 months (many firms require 24 months) and received a confirmed intracranial meningioma diagnosis are the primary qualifying claimants.

Qualification also requires that the claim be filed within the applicable state statute of limitations, typically two to three years from the date the claimant knew or should have known about the connection.

Medical records confirming meningioma diagnosis and documentation of Depo-Provera use history are required to pursue a claim.

Is the Depo-Provera lawsuit a class action?

The Depo-Provera lawsuit is not a class action. It is a mass tort MDL, which means each plaintiff maintains an individual case with individual damages.

In MDL 3140, compensation is evaluated separately for each claimant based on their specific injury, duration of drug use, and documented losses, rather than being divided among a class.

This structure is generally more favorable for serious injury claimants than a class action would be.

What is the filing deadline for the Depo-Provera lawsuit?

There is no single universal filing deadline. Each state's product liability statute of limitations applies, ranging from two to three years depending on the state.

The discovery rule in most states means the clock runs from when the claimant knew or should have known that Depo-Provera may have caused their meningioma, not necessarily from the date of diagnosis.

Claimants in Florida, Texas, and Georgia face the most time pressure due to shorter or recently reduced limitations periods.

How do I find an attorney for the Depo-Provera lawsuit?

Seek an attorney who specifically handles pharmaceutical mass tort or MDL litigation, not a general personal injury practitioner.

Legitimate mass tort attorneys handle Depo-Provera cases on a contingency basis with no upfront cost to the client.

Confirm you are speaking directly with a licensed attorney at the firm that will actively represent you, not a lead generation service.

Closing

The Depo-Provera lawsuit is one of the largest active pharmaceutical mass torts in the federal court system. The science supporting the meningioma link is credible, the MDL is structured, and claim volume is growing.

Women who used Depo-Provera for an extended period and subsequently received a meningioma diagnosis should treat the statute of limitations as an immediate concern. The discovery rule provides protection, but it does not eliminate the deadline.

Consulting a pharmaceutical product liability attorney who actively works in MDL 3140 is the concrete next step. A proper case evaluation requires your medical records and your Depo-Provera use history, and most attorneys in this space will conduct that evaluation at no charge.

If you are curious, also see Hall and Oates Lawsuit: The 2026 Case Update Explained